# DARZALEX FASPRO (daratumumab and hyaluronidase-fihj)

Type: Product

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/darzalex-faspro-daratumumab-and-hyaluronidase-fihj
Canonical HTML page: https://getbiobrief.com/entity/darzalex-faspro-daratumumab-and-hyaluronidase-fihj

## Recent coverage (1 stories)

### Halozyme's ENHANZE drives 47.7% revenue surge and FY26 EPS guidance 8% above Street
2026-08-12 02:48:54 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Halozyme's Q2 2026 earnings showcased accelerating adoption of its ENHANZE drug delivery technology, with royalties from subcutaneous biologics like DARZALEX FASPRO pushing revenue up 47.7% YoY. The company issued FY2026 EPS guidance of $8.65-$9.00, handily beating consensus, signaling sustained growth from its partnered pipeline.
Full story: https://getbiobrief.com/story/halozyme-enhanze-partner-royalties-q2-2026-guidance

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.